Our objective is to develop a functional precision medicine platform designed to directly identify tailored drug regimens that target individual patient cancer cells and give benefit to the same donors by supporting clinical decision-making. We demonstrate our ex vivo drug sensitivity screening platform for precision medicine using Leukaemia and Multiple Myeloma samples from a South African patient cohort as proof of concept.
Reference:
Kenmogne, V., Takalani, A., Nweke, E., Takundwa, M.M., Fabian, J., Maher, H., Du Toit, J. & Philip-Cherian, V. et al. 2023. Establishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohort. Hematology, Transfusion and Cell Therapy, 45(3). http://hdl.handle.net/10204/13385
Kenmogne, V., Takalani, A., Nweke, E., Takundwa, M. M., Fabian, J., Maher, H., ... Govindaraj, D. (2023). Establishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohort. Hematology, Transfusion and Cell Therapy, 45(3), http://hdl.handle.net/10204/13385
Kenmogne, VL, AMT Takalani, EE Nweke, Mutsa M Takundwa, June Fabian, Heather Maher, Justin Du Toit, V Philip-Cherian, PF Fru, and DBT Govindaraj "Establishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohort." Hematology, Transfusion and Cell Therapy, 45(3) (2023) http://hdl.handle.net/10204/13385
Kenmogne V, Takalani A, Nweke E, Takundwa MM, Fabian J, Maher H, et al. Establishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohort. Hematology, Transfusion and Cell Therapy, 45(3). 2023; http://hdl.handle.net/10204/13385.
ResearchSpace
